chang earn forecast
baffl stock reaction org revenue print
reiter outperform pt tweak
given amount debat revenu trajectori head
thought organ revenue print ex impact
solid came well expect said one
concern question sustain given
scale thought driver revenu strength provid confid
sustain diabet de stent pain therapi
grow doubl digit high singl recal area
saw signific disrupt previou qs new product driven
inflect point sustain next qs highlight
us commentari around mm revenu tie vbc
valu base contract mostli us think bode well
chang healthcar landscap think well ahead
peer earli head start give advantag
flip side ep commentari increment headwind lesser
interest incom loss tsa incom suggest off-set benefit
fx st number may come slightli stock
result offici baffl understand optic
number come slightli believ adequ captur
forward price-to-earnings multipl sub price-to-earnings basi like
print organ top-line next qs easi comp
share repres buy opportun today weak
organ sale growth strength across busi unit
geographi
pain therapi return growth sever quarter
diabet sensor capac improv effort track
mid teen growth de stent
slight push timelin surgic robot platform previous
expect first next month
increment headwind relat fx hedg impli
hundr bp oper ep headwind fy
offset ep tailwind fx net net flat
continu next page
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
foreign exchang impact sale tailwind mm mm
oper margin headwind due fx
foreign exchang impact ep headwind
free high singl digit growth compar basi compound annual actual basi low
foreign exchang impact sale tailwind mm mm
sale growth segment
cardiac vascular group cvg driven new product partial off-set tough comp
minim invas therapi group mitg driven new product partial off-set tough comp
restor therapi group rtg balanc impact slower spine market partial off-set
continu growth pain therapi strength brain therapi compar sale mm
diabet doubl digit driven increas sensor suppli strength minim launch us
oper margin headwind due fx
share count roughli flat rest year
foreign exchang impact ep headwind compar
earli fy commentari explicit guid come earn call
compar constant currenc sale growth mid singl digit line versu long term guidanc
foreign exchang impact sale tailwind mm
sale growth segment
cardiac vascular group cvg mid singl digit growth
tax rate continu refin estim continu expect slightli lower effect tax rate
continu drive oper margin improv ep leverag
potenti headwind fy ep altogeth hundr bp headwind ep growth estim approxim
less interest incom due plan posit invest provid greater flexibl support mdt capit
full year benefit stock base compens account chang anniversari
begin transit servic relat divestitur
work partial off-set impact headwind
foreign exchang impact ep tailwind rate remain current level
divestitur impact mm sale ep impact
real major chang market
expect surgic procedur remain versu
diabet procedur ramp decemb tail januari
 use
debt paydown bn debt matur plan retir
court uphold prior settlement pay larg tax settlement
expect bn annual gross run rate save mm mm year next five year
expect lower half earlier year upper half later year
save drop ep look off-set price pressur reinvest busi
product updat pipelin
excit seen date though timelin first human use shift
sort hiccup uncommon deal system complex
provid color commentari june investor meet
sensor manufactur progress well contribut growth
refer point product higher versu saw
also continu see mard line seen clinic trial ramp product
expect abl meet unconstrain demand end
guardian connect stand-alone cgm us time applic fda expect approv shortli
transit anima custom also contribut diabet growth even exclud doubl digit growth
take share pacemak given micra crt-p next gener wireless pacemak azur
pleas level uptak tyrx program hospit particip program
risk share program beyond tyrx hf reduct adaptiv crt smart shock program dcb
combin program cover mm mostli us base devic sale
chang market dynam overal market growth low
market share captur realli driven evolut expand indic geograph expans japan
resolut onyx launch us japan drive growth
resolut onyx resolut integr allow provid multipl price point custom
believ continu grow cvg market
think spine market flat slightli procedur growth off-set price declin
expect see benefit mazor agreement come quarter
reflect way place piec equip account increment spine share month lag
around decemb januari time frame mazor integr broader spine technolog certain
advanc featur work implant
still earli respons orthoped valu base orthoped offer
date mdt biannual investor meet held june new york
valuat methodolog base mix discount cash flow analysi rel valuat multipl
risk valuat includ regulatori risk overal market risk well unforeseen event relat individu cover
compani broader sector includ new competit product technolog
articl articl
time dissemin februari et
analyst vijay kumar brittani henderson primarili respons prepar research report attest follow
view opinion render research report reflect person view subject compani issuer
part research analyst compens directli relat specif recommend view research report
